Peter Bergethon
Head Quantitative and Clinical Technologies
Biogen

I lead the effort to transform clinical trials and humanize drug discovery by encouraging the transition of clinical trial measures from a qualitative to a quantitative discipline. The QMCT transformation will advance Biogen’s leadership in neuroscience therapeutics and personalized medicine.  I came to Biogen in 2017 from Pfizer Worldwide Research and Development where I was Vice President and Head of the Pfizer Innovation Research Lab within the Early Clinical Development group.   Before joining the biopharmaceutical industry in 2012 I spent 30 years in academic medicine as a denizen of the Boston shark tank where I had attained the important status of possessing an assigned parking space within 20 yards of my laboratory! In trade for that privilege I worked as a Professor at Boston University and Tufts University in the Departments of Biochemistry, Neurology, Neurobiology & Anatomy, and Biomedical Engineering.
 
I graduated from Williams College with honors in biology for research in neurocybernetics and then earned an M.D. from Jefferson Medical College and am board certified in internal medicine and neurology following dual residencies at Boston City Hospital. My formal science training was through NIH Physician-Scientist training in biophysical chemistry at Boston University School of Medicine. I then completed a fellowship training in EEG and neurophysiology at Lahey Clinic-Hitchcock Medical Center, Burlington, MA. I won the Founder’s Award from the American Academy of Neurology in 1995 for work showing the arrest and reversal of neuropathy in familial amyloidotic neuropathy following liver transplantation thus participating in helping establish a cure in a fatal disease (the first of two cures to have the privilege to contribute to). This experience drives me at Biogen. I want one more before retiring!
 
My research and interests have always spiraled around a core question: "What is the physical and systemic basis for creativity and intelligent behavior and how could such behavior be practically constructed or reconstructed?" This core query continues to form the basis for the approach that QMCT takes toward transforming Biogen’s approach to neuroscience therapeutics. The ultimate thrust of my interest is the design, construction and operation of “intelligent machines” inspired by biological understanding. By any measure I have lived a charmed scientific existence in which I have been paid to imagine and build toward a world dominated by the Matrix or SkyNet. I love to write and read and have written or contributed to over 130 research papers and books including the SymmetryScience K-8 science education program - a science literacy program teaching science as “way of looking at the world” and am the single author of “The Physical Basis of Biochemistry: The Foundations of Molecular Biophysics, 2nd Ed., (New York:Springer-Verlag, 2010). When I retire I plan to write science fiction in the hard speculative-fiction genre and return to inventing advanced intelligent computing systems.
 
My wife Cindy and I are avid readers, scuba divers and amateur geologists who love being outdoors or anywhere our reading will take us. We enjoy the company of our two “boyz”, Brinkley, an 11 year old Golden Retriever and Maxell, a 9 year old Golden Doodle who watch all the Patriots, Red Sox and Green Bay Packers games with us whenever they can. Our daughter Kristin is a physician in Boston and joins us at home whenever her schedule allows.